ArticleSouth Asian journal of cancer2022

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma.

Sanju Cyriac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.